Cite
HARVARD Citation
Ladha, A. et al. (2021). Routine use of gemtuzumab ozogamicin in 7 + 3-based inductions for all 'non-adverse' risk AML. Leukemia & lymphoma. 62 (6), pp. 1510-1513. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Ladha, A. et al. (2021). Routine use of gemtuzumab ozogamicin in 7 + 3-based inductions for all 'non-adverse' risk AML. Leukemia & lymphoma. 62 (6), pp. 1510-1513. [Online].